S108: A SYSTEMATIC POST-MARKETING (PM) REVIEW OF RARE INFUSION-RELATED REACTIONS (IRRS) PRESENTING AS PAIN EVENTS DURING OR AFTER CRIZANLIZUMAB INFUSION IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
J Kanter,
A Shah,
V Joshi,
H Mehta,
M Levine,
U Arunagiri,
J Paulose,
B Donohue,
A Scalera,
D Manwani
Affiliations
J Kanter
1 University of Alabama, Birmingham, UNITED STATES
A Shah
2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES
V Joshi
3 Novartis Healthcare Private Limited, Hyderabad, INDIA
H Mehta
3 Novartis Healthcare Private Limited, Hyderabad, INDIA
M Levine
2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES
U Arunagiri
2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES
J Paulose
2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES
B Donohue
2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES
A Scalera
2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES
D Manwani
4 Albert Einstein College of Medicine, The Children’s Hospital at Montefiore, New York, UNITED STATES
